Valuation conundrum of healthcare-related stocks in US and M’sia


THE United States, which is the epicentre of the Covid-19 pandemic, is the base for some of the world’s largest healthcare companies. These companies are in the race to find a vaccine for the virus and have from time to time disclosed the progress of finding a wonder drug to prevent the spread of the virus.

However, the valuations of the more established pharmaceutical companies have remained sober even though the companies are in the forefront of the search to find a vaccine.

Subscribe or renew your subscriptions to win prizes worth up to RM68,000!

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Radium’s net profit up to RM4.8mil in 3Q
7-Eleven’s quarterly revenue climbs
SimeProp seeks quality assets for recurring income
Lower interest costs buoy TSH nine-month showing
Zetrix a profit driver for MyEG Services
NFO segment to sustain Sports Toto’s earnings
Thong Guan spreading its wings to Europe, America
Hap Seng bottom line in four-fold rise
Mixed views on PetChem on higher interest expense
No new impetus seen for JETP under Trump

Others Also Read